CTRI/2019/08/020566招募中2 期
A phase II study of hormone therapy alone in low-grade serous cancer (ovary/fallopian tube/peritoneum) following debulking surgery. - LOSECT
试验速览
- 阶段
- 2 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •a. Age 18 â?? 75 years
- •b. Stage II â?? stage IV LGSC
- •c. Patients who have undergone either upfront cytoreductive surgery or who have received neoadjuvant chemotherapy and then underwent cytoreductive surgery.
- •d. ER and /or PR positive cases.
排除标准
- •a. Patients who received chemotherapy post cytoreductive surgery.
- •b. Recurrent cases of low-grade serous cancer of ovary/peritoneum.
- •c. Cells showing morphological features of LGSC with moderate nuclear atypia and >= 70% cells showing diffuse strong P53 mutations or null type P53.
- •d. ER and PR negative LGSC
- •e. Exclude if fertility sparing conservative surgery is undertaken
- •f. Low grade serous ovarian/fallopian tube/ cancer during pregnancy
研究者
相似试验
已完成
不适用
The Effect of Low Dose Hormone Replacement Therapy or Raloxifene on Bone and Lipid Metabolism in Hemodialysis PatientsPostmenopausal osteopenia in hemodialysis patientsJPRN-C000000390Department of Nephrology, Osaka University School of Medicine39
招募中
Unknown
Retrospective study of the efficacy of hormonal therapy for advanced or recurrent low-grade endometrial stromal sarcomaunresectable advanced or recurrent low-grade endometrial stromal sarcomaJPRN-UMIN000050780Shizuoka Cancer Center40
进行中（未招募）
不适用
Phase I/II clinical trial:Immunotherapy of hormone-refractory prostate cancer patients with dendritic cell-based vaccine (Fáze I/II klinické studie imunoterapie hormonálne refrakterního karcinomu prostaty pomocí vakcinace dendritickými bunkami) - Imunoterapie karcinomu prostaty dendritickými bunkamiPatients with hormone-refractory prostate cancerEUCTR2009-017295-24-CZniversity Hospital Motol
已完成
2 期
A Randomized Phase II Study of Maintenance Hormone Therapy with or without Capecitabine after Induction Chemotherapy with Bevacizumab plus Paclitaxel in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer (KBCSG-TR1214)Breast cancerJPRN-UMIN000008662KBCSG-TR(Kinki Breast Cancer Study Group-TR)120
进行中（未招募）
1 期
Study evaluation of 2nd hormone line response by -[18F]fluoro-17ß-œstradiol (FES) PET/CT in metastatic breast cancer patientsMedDRA version: 19.0Level: LLTClassification code 10007305Term: Carcinoma breastSystem Organ Class: 100000004864EUCTR2016-002120-83-FRINSTITUT DE CANCEROLOGIE DE L'OUEST RENE GAUDUCHEA